drugset / Trial / NCT06165822

A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

NCT06165822

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of Itraconazole Capsules/Rifampicin Capsules on pharmacokinetics of TQB3909 tablets in vivo, and the safety of TQB3909 tablets and combined with Itraconazole Capsules/Rifampicin Capsules after single oral dose.

Timeline

Start
2023-12
Primary completion
2024-01
Completion
2024-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 0.2 g
Subject Rifampin Small molecule 0.6 g
Subject TQB3909 Unknown 100 mg Oral

Indications